We have summarized common and differential functions of HMGB1 and HMGB2 proteins
with reference to pathological processes, with a special focus on cancer. Currently, several
“omic” approaches help us compare the relative expression of these 2 proteins in healthy and cancerous
human specimens, as well as in a wide range of cancer-derived cell lines, or in fetal versus
adult cells. Molecules that interfere with HMGB1 functions, though through different mechanisms,
have been extensively tested as therapeutic agents in animal models in recent years, and their effects
are summarized. The review concludes with a discussion on the perspectives of HMGB molecules
as targets in prostate and ovarian cancers.
No Supplementary Data
No Article Media
EXPRELA Group, Centro de Investigacións Científicas Avanzadas (CICA), Departamento de Bioloxía. Facultade de Ciencias, INIBIC- Universidade da Coruña, Campus de A Coruña, 15071, A Coruña, Spain.
Translational Cancer Research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Carretera del Pasaje s/n, 15006 A Coruña, Spain.
Appeared or available online: July 17, 2019